Kodiak Sciences Inc. (KOD) stock
KODNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$111.19+2.94 (+2.72%)
Close on Nov 13, 2026Market cap $6.99BP/E –Yield –
Kodiak Sciences r&d expenses
Research and development expenses are spending on new products and technology.
Kodiak Sciences's R&D Expenses for the twelve months ending Sep 30, 2026 was $208.43M, up 23.6% year over year. For fiscal 2025 it was $182.37M, up 44.6% from the year before. The highest annual figure on record is $267.59M in fiscal 2022.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $182.37M | +44.6% |
| FY2024 | Dec 31, 2024 | $126.10M | -38.9% |
| FY2023 | Dec 31, 2023 | $206.30M | -22.9% |
| FY2022 | Dec 31, 2022 | $267.59M | +23.1% |
| FY2021 | Dec 31, 2021 | $217.34M | +102.4% |
| FY2020 | Dec 31, 2020 | $107.39M | +186.3% |
| FY2019 | Dec 31, 2019 | $37.51M | +99.6% |
| FY2018 | Dec 31, 2018 | $18.79M | -14.7% |
| FY2017 | Dec 31, 2017 | $22.02M | +56.7% |
| FY2016 | Dec 31, 2016 | $14.05M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $58.30M | +15.5% |
| Q2 FY2026 | Jun 30, 2026 | $56.08M | +31.2% |
| Q1 FY2026 | Mar 31, 2026 | $48.55M | +11.2% |
| Q4 FY2025 | Dec 31, 2025 | $45.49M | +43.2% |
| Q3 FY2025 | Sep 30, 2025 | $50.48M | +58.3% |
| Q2 FY2025 | Jun 30, 2025 | $42.76M | +31.5% |
| Q1 FY2025 | Mar 31, 2025 | $43.64M | +45.8% |
| Q4 FY2024 | Dec 31, 2024 | $31.77M | -31.9% |
| Q3 FY2024 | Sep 30, 2024 | $31.88M | -11.9% |
| Q2 FY2024 | Jun 30, 2024 | $32.51M | -51.4% |
| Q1 FY2024 | Mar 31, 2024 | $29.93M | -47.0% |
| Q4 FY2023 | Dec 31, 2023 | $46.63M | -16.7% |
| Q3 FY2023 | Sep 30, 2023 | $36.19M | -41.3% |
| Q2 FY2023 | Jun 30, 2023 | $66.96M | -9.2% |
| Q1 FY2023 | Mar 31, 2023 | $56.52M | -25.8% |
| Q4 FY2022 | Dec 31, 2022 | $55.99M | -25.9% |
| Q3 FY2022 | Sep 30, 2022 | $61.68M | +10.1% |
| Q2 FY2022 | Jun 30, 2022 | $73.74M | +62.4% |
| Q1 FY2022 | Mar 31, 2022 | $76.18M | +88.9% |
| Q4 FY2021 | Dec 31, 2021 | $75.60M | +102.4% |
| Q3 FY2021 | Sep 30, 2021 | $56.00M | +91.1% |
| Q2 FY2021 | Jun 30, 2021 | $45.40M | +120.9% |
| Q1 FY2021 | Mar 31, 2021 | $40.34M | +100.0% |
| Q4 FY2020 | Dec 31, 2020 | $37.36M | +191.2% |
| Q3 FY2020 | Sep 30, 2020 | $29.31M | +189.7% |
| Q2 FY2020 | Jun 30, 2020 | $20.56M | +132.6% |
| Q1 FY2020 | Mar 31, 2020 | $20.17M | +252.4% |
| Q4 FY2019 | Dec 31, 2019 | $12.83M | +87.3% |
| Q3 FY2019 | Sep 30, 2019 | $10.12M | +114.8% |
| Q2 FY2019 | Jun 30, 2019 | $8.84M | +146.1% |
| Q1 FY2019 | Mar 31, 2019 | $5.72M | +57.1% |
| Q4 FY2018 | Dec 31, 2018 | $6.85M | -68.9% |
| Q3 FY2018 | Sep 30, 2018 | $4.71M | +149487.0% |
| Q2 FY2018 | Jun 30, 2018 | $3.59M | – |
| Q1 FY2018 | Mar 31, 2018 | $3.64M | – |
| Q4 FY2017 | Dec 31, 2017 | $22.01M | – |
| Q3 FY2017 | Sep 30, 2017 | $3.15K | – |
See a number that looks wrong?